Press Releases Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Market Closed - Nasdaq Other stock markets 04:30:01 2024-06-04 pm EDT			5-day change	1st Jan Change
0.5098 ^USD	-5.24%		+14.87%	+12.04%

May. 13	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Mar. 21	Shuttle Pharmaceuticals Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Press Releases

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	May. 22	AQ
Shuttle Pharma Provides First Quarter 2024 Corporate Update	May. 14	AQ
Shuttle Pharmaceuticals to Present at the Planet MicroCap Showcase: VEGAS 2024 on Wednesday, May 1, 2024 & 1x1 Meetings on Thursday, May 2, 2024	Apr. 23	AQ
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on April 4, 2024	Apr. 03	AQ
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	Mar. 25	AQ
Shuttle Pharma Provides Fourth Quarter 2023 Corporate Update	Mar. 22	PR
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on March 6, 2024	Mar. 05	AQ
Shuttle Pharma Announces Its Intent to Pursue a Rights Offering	Feb. 13	PR
Shuttle Pharma to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	Jan. 23	PR
Shuttle Pharmaceuticals Submits IND Application to the U.S. FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	Dec. 12	AQ
Shuttle Pharmaceuticals to Present at the Emerging Growth Conference on December 7, 2023	Nov. 30	PR
Shuttle Pharmaceuticals Provides Third Quarter 2023 Corporate Update	Nov. 14	PR
Shuttle Pharma Advances Prostate Cancer Predictive Biomarker Program through Exclusive License Agreement	Nov. 01	AQ
Shuttle Pharmaceuticals : Pharma Advances Prostate Cancer Predictive Biomarker Program Through Exclusive License Agreement - Form 8-K	23-10-30	PU
Shuttle Pharma to Participate in the Lytham Partners Fall 2023 Investor Conference	23-10-10	PR
Shuttle Pharma Announces Results of Pre-IND Meeting with FDA for Ropidoxuridine Phase II Clinical Trial for Patients with Glioblastoma	23-09-25	PR
Shuttle Pharma Participates in Hampton University Proton Therapy Institute Prostate Cancer and Men's Health Fair	23-09-14	AQ
Shuttle Pharma Expands Patent Coverage on HDAC Inhibitor Platform	23-09-11	PR
Shuttle Pharma's Selective HDAC6 Inhibitor Shown to Stimulate Innate Immune Response in Pre-clinical Studies, as Reported in Molecular Cancer Therapeutics	23-08-30	AQ
Shuttle Pharmaceuticals Provides Second Quarter 2023 Corporate Update	23-08-15	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Shuttle Pharmaceuticals Holdings, Inc.

Equities

SHPH

US8256932034

Press Releases

Filters